Ibrutinib-bendamustine-rituximab combo promising for older patients with mantle-cell lymphoma

A treatment combination comprising the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus bendamustine and rituximab, followed by rituximab maintenance therapy, improved progression-free survival (PFS) in older patients with untreated mantle-cell lymphoma, according to results of the SHINE* trial presented at ASCO 2022.

Methotrexate proven safe, effective as first-line immunomodulator in paediatric Crohn's disease
Use of methotrexate (MTX) appears safe and effective as first-line immunomodulator for maintenance therapy in children with Crohn’s disease (CD), suggests a study presented at the 54th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN 2022).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in